Association of Circulating Antibody-Secreting Cell Maturity With Disease Features in Primary Sjögren's Syndrome
- PMID: 36533856
- DOI: 10.1002/art.42422
Association of Circulating Antibody-Secreting Cell Maturity With Disease Features in Primary Sjögren's Syndrome
Abstract
Objective: B cell hyperactivity plays an important role in primary Sjögren's syndrome (SS). We undertook this study to better understand the B cell effector branch, namely antibody-secreting cells (ASCs) in primary SS, and to examine the quantity, maturity, and inflammatory properties of ASCs in primary SS patients.
Methods: Circulating ASCs, defined as CD3-CD14-CD27+CD38++ cells, from 21 primary SS patients and 10 healthy controls were assessed using spectral flow cytometry. Expression levels of relevant ASC markers relating to maturity, survival, and inflammatory status were analyzed using a t-distributed stochastic neighbor embedding approach. Correlation of ASC properties with primary SS disease parameters was assessed.
Results: ASCs were more abundant in peripheral blood from primary SS patients than from healthy controls (mean ± SD 3.1 ± 5.1 cells/μl versus 1.1 ± 1.0 cells/μl, respectively; P = 0.048) and displayed a more mature phenotype (mean ± SD CD19- ASCs 0.37 ± 1.21 cells/μl versus 0.06 ± 0.11 cells/μl, respectively; P = 0.005). An inflammatory CXCR3+ phenotype of ASCs correlated positively with our newly developed ASC maturity index (r = 0.568, P = 0.007) but correlated negatively with antiinflammatory interleukin-10 expression (r = -0.769, P < 0.001). ASCs with a higher maturity index also demonstrated higher levels of the pro-survival protein myeloid cell leukemia 1 (r = 0.567, P = 0.007). Frequency and/or maturity of ASCs correlated with several primary SS disease parameters, such as antinuclear antibody and anti-La/SSB titers, salivary gland focus scores, and ocular staining scores.
Conclusion: Quantity and maturity of ASCs in primary SS patients are increased and correlate with disease parameters. A higher maturity index of ASCs marks a pro-survival and proinflammatory phenotype. Altogether, B cell hyperactivity in primary SS extends to the peripheral ASC compartment, raising potential for ASCs as future biomarkers or targets for primary SS treatment.
Trial registration: ClinicalTrials.gov NCT02067910.
© 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
References
REFERENCES
-
- Maciel G, Crowson CS, Matteson EL, et al. Prevalence of primary Sjögren's syndrome in a US population-based cohort: primary SS prevalence. Arthritis Care Res (Hoboken) 2017;69:1612-6.
-
- Kroese FGM, Abdulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjögren's syndrome [review]. Expert Rev Clin Immunol 2014;10:483-99.
-
- van Ginkel MS, Haacke EA, Bootsma H, et al. Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren's syndrome patients. Clin Exp Rheumatol 2019;37:42-8.
-
- Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, et al. Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. Arthritis Rheum 2005;52:1517-21.
-
- Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome: ectopic germinal center formation in Sjögren's syndrome. Arthritis Rheum 2003;48:3187-201.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
